Document is current

Any future updates will be listed below

Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA

Crossref DOI link: https://doi.org/10.1038/s41571-025-01048-4

Published Online: 2025-06-18

Published Print: 2025-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark